Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kiora Pharmaceuticals, Inc. (KPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.15-0.57 (-8.48%)
At close: 04:00PM EDT
6.20 +0.05 (+0.81%)
After hours: 07:58PM EDT
Advertisement

Kiora Pharmaceuticals, Inc.

1371 East 2100 South
Suite 200
Salt Lake City, UT 84105
United States
781 788 8869
https://www.kiorapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Dr. Brian M. Strem Ph.D.Pres, CEO, Principal Financial & Accounting Officer and Director383.82kN/A1979
Dr. Eric J. Daniels M.B.A., M.D.Chief Devel. OfficerN/AN/A1973
Dr. Stefan Sperl Ph.D.Exec. VP of CMC & OperationsN/AN/AN/A
Ms. Melissa ToscaExec. VP of Fin.N/AN/AN/A
Dr. MaryJane Rafii Ph.D.ConsultantN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Kiora Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement